{
    "1": {
        "question": "What was the primary goal of the study?",
        "options": {
            "A": "To compare the outcome of patients with NVAF treated with OAC only versus OAC with an antiplatelet.",
            "B": "To measure the long-term effects of OAC on systemic atherosclerosis.",
            "C": "To determine the effectiveness of statins in reducing myocardial infarction after stroke.",
            "D": "To evaluate the effects of lifestyle changes on the recurrence of strokes.",
            "E": "To investigate the impact of new anticoagulant drugs on NVAF.",
            "F": "I don't know"
        }
    },
    "2": {
        "question": "What was the hazard ratio for all-cause mortality when using OAC\u2009+\u2009antiplatelet compared to OAC alone, according to the inverse probability of treatment weighting?",
        "options": {
            "A": "0.63",
            "B": "0.34",
            "C": "1.01",
            "D": "0.48",
            "E": "2.19",
            "F": "I don't know"
        }
    },
    "3": {
        "question": "Which antiplatelet agent was most frequently prescribed to patients in the OAC\u2009+\u2009antiplatelet group?",
        "options": {
            "A": "Clopidogrel",
            "B": "Triflusal",
            "C": "Aspirin",
            "D": "Ticlopidine",
            "E": "Cilostazol",
            "F": "I don't know"
        }
    },
    "4": {
        "question": "Which outcome showed a significant difference between OAC\u2009+\u2009antiplatelet and OAC-only groups, as per the inverse probability of treatment weighting?",
        "options": {
            "A": "Hemorrhagic stroke",
            "B": "Myocardial infarction",
            "C": "Bleeding events",
            "D": "Gastrointestinal bleeding",
            "E": "Stroke recurrence",
            "F": "I don't know"
        }
    },
    "5": {
        "question": "What proportion of the study participants were male?",
        "options": {
            "A": "50.0%",
            "B": "64.3%",
            "C": "53.2%",
            "D": "59.3%",
            "E": "68.2%",
            "F": "I don't know"
        }
    },
    "6": {
        "question": "What was the most common comorbid atherosclerotic condition observed in the study population?",
        "options": {
            "A": "Peripheral artery occlusive disease",
            "B": "Cerebral atherosclerosis",
            "C": "Coronary artery occlusive disease",
            "D": "Aortic arch atheroma",
            "E": "Carotid artery disease",
            "F": "I don't know"
        }
    },
    "7": {
        "question": "What statistical method was employed to adjust for baseline characteristic differences between the two treatment groups?",
        "options": {
            "A": "Linear regression",
            "B": "ANOVA",
            "C": "Inverse probability of treatment weighting",
            "D": "Logistic regression",
            "E": "Chi-square test",
            "F": "I don't know"
        }
    },
    "8": {
        "question": "What percentage of patients in the study were treated with direct oral anticoagulants (DOAC) in the OAC alone group?",
        "options": {
            "A": "45.0%",
            "B": "96.6%",
            "C": "65.2%",
            "D": "34.8%",
            "E": "55.0%",
            "F": "I don't know"
        }
    },
    "9": {
        "question": "After adjusting baseline characteristics using inverse probability of treatment weighting, which subgroup showed interaction effects with antithrombotic regimens?",
        "options": {
            "A": "Age",
            "B": "Gender",
            "C": "Cerebral or coronary stents or hypertension",
            "D": "Diabetes",
            "E": "Smoking status",
            "F": "I don't know"
        }
    },
    "10": {
        "question": "What was the percentage risk of recurrent ischemic stroke in patients who received OAC\u2009+\u2009antiplatelet?",
        "options": {
            "A": "3.1%",
            "B": "8.8%",
            "C": "2.9%",
            "D": "6.1%",
            "E": "11.2%",
            "F": "I don't know"
        }
    },
    "11": {
        "question": "According to the study, how did the proportion of patients with hypertension between OAC\u2009+\u2009antiplatelet and OAC groups compare in unadjusted analysis?",
        "options": {
            "A": "Less likely in OAC\u2009+\u2009antiplatelet group",
            "B": "More likely in OAC\u2009+\u2009antiplatelet group",
            "C": "Equal in both groups",
            "D": "Significantly lower in OAC group",
            "E": "Significantly higher in OAC group",
            "F": "I don't know"
        }
    },
    "12": {
        "question": "How many patients received a combination of OAC and an antiplatelet agent at discharge?",
        "options": {
            "A": "296",
            "B": "445",
            "C": "149",
            "D": "103",
            "E": "193",
            "F": "I don't know"
        }
    },
    "13": {
        "question": "Which factor was identified as an independent determinant for using OAC\u2009+\u2009antiplatelet?",
        "options": {
            "A": "Cerebral artery stenosis",
            "B": "Diabetes",
            "C": "Coronary stent",
            "D": "Age",
            "E": "Current smoking",
            "F": "I don't know"
        }
    },
    "14": {
        "question": "What was the median age of the study participants?",
        "options": {
            "A": "85",
            "B": "78",
            "C": "70",
            "D": "63",
            "E": "75",
            "F": "I don't know"
        }
    },
    "15": {
        "question": "Which figure depicts the Kaplan\u2013Meier survival curve comparison according to antithrombotic regimen?",
        "options": {
            "A": "Figure 1",
            "B": "Figure 2",
            "C": "Figure 3",
            "D": "Figure 4",
            "E": "Supplementary Figure 1",
            "F": "I don't know"
        }
    },
    "16": {
        "question": "How often was statin prescribed at discharge in the study cohort?",
        "options": {
            "A": "50.0%",
            "B": "80.0%",
            "C": "97.3%",
            "D": "90.5%",
            "E": "85.1%",
            "F": "I don't know"
        }
    },
    "17": {
        "question": "What percentage of patients treated with DOAC alone were observed to receive an insufficient dose?",
        "options": {
            "A": "25.0%",
            "B": "9.0%",
            "C": "10.4%",
            "D": "12.5%",
            "E": "5.0%",
            "F": "I don't know"
        }
    },
    "18": {
        "question": "In the unadjusted analysis, what was the observed hazard ratio for the incidence of bleeding events when comparing OAC to OAC\u2009+\u2009antiplatelet?",
        "options": {
            "A": "0.63",
            "B": "5.99",
            "C": "1.12",
            "D": "0.34",
            "E": "2.19",
            "F": "I don't know"
        }
    },
    "19": {
        "question": "Which variables were more common in patients receiving OAC\u2009+\u2009antiplatelet versus OAC alone?",
        "options": {
            "A": "Diabetes, Dyslipidemia, Low GFR",
            "B": "Hypertension, CAOD, Cerebral and Coronary stents",
            "C": "Age, Smoking, Initial NIHSS",
            "D": "Current smoking, PAOD, CHF",
            "E": "Sex, Aortic atheroma, High-dose statin",
            "F": "I don't know"
        }
    },
    "20": {
        "question": "According to Table 2, what was the hazard ratio for ischemic stroke when using OAC\u2009+\u2009antiplatelet compared to OAC alone in the adjusted groups?",
        "options": {
            "A": "0.48",
            "B": "6.12",
            "C": "2.76",
            "D": "1.01",
            "E": "0.34",
            "F": "I don't know"
        }
    }
}